Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms TD-016 |
Target |
Action inhibitors |
Mechanism ALK inhibitors(Anaplastic lymphoma kinase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC57H74ClN9O8S2 |
InChIKeyZZMFLQGXQVEFQJ-UBBOFEIVSA-N |
CAS Registry2162120-63-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
ALK positive Non-Small Cell Lung Cancer | Preclinical | South Korea | 01 Oct 2018 | |
ALK positive Non-Small Cell Lung Cancer | Preclinical | South Korea | 01 Oct 2018 |